Article

Biopsy at low PSA levels may translate into better clinical outcomes

Chicago-A biopsy of men with PSA levels of 2.6 to 4.0 ng/mL may detectorgan-confined prostate cancer more often than a biopsy in men with a PSAlevel >4.0 ng/mL, according to a large study from Washington University,St. Louis, presented yesterday. This may result in better clinical outcomes,including a lower biochemical progression rate.

Related Videos
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
1 expert in this video
Perry Xu, MD, answers a question during Zoom video interview
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Human Body Organs (Urinary Bladder) | Image Credit: @ magicmine - stock.adobe.com
April 21st 2025

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

Hannah Clarke
Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
Introducing Pearls & Perspectives, with Amy Pearlman, MD!
April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD
Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.
blur image background of corridor in hospital or clinic image | Image Credit: @ whyframeshot - stock.adobe.com
April 18th 2025

U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers

Michigan Institute of Urology
Ambulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Urologists perform first remote robot-assisted HIFU for prostate cancer
April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke
“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
© 2025 MJH Life Sciences

All rights reserved.